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Summary In the present study we have used the alkaline elution technique to study the effect of
misonidazole (MISO) on the initial amount of DNA cross-linking in various normal and neoplastic tissues of
C3H mice treated with nitrogen mustard (HN2) in vivo. Tissue samples for analysis of the cross-links were
prepared 1 h after injection with HN2 to minimize the effect of subsequent repair processes on the yield of
lesions. For mice receiving HN2 alone, the greatest level of cross-linking was found in spleen and jejunum,
with the liver showing the lowest level. In animals that had been pretreated with MISO (1 mgg-1, i.p.) for
0.5h prior to injection with HN2, the amount of cross-linking in the spleen and jejunum was not affected by
MISO; however, in all other tissues that were examined, cross-linking was enhanced by MISO to a varying
extent depending on the specific tissue. The greatest enhancement was observed in the liver ( x 6) and kidney
(x 3.1), both of these tissues showing a greater enhancement than either of the two fibrosarcomas. The
potentiation of HN2 cross-linking in a particular tissue correlated well with two cellular processes that are
known to be nitroreduction-dependent in vitro, namely, the degree of MISO-induced GSH depletion and the
binding of MISO to cellular macromolecules. Thus, the potentiation ofcross-linking in normal tissues such as
liver and kidney, and by inference in tumours, may be intimately related to the generation and/or
accumulation ofnitro-reduced MISO metabolites in those tissues.
The potentiation of many antitumour drugs by the
hypoxic cell radiosensitizer misonidazole (MISO) is
now well documented (McNally, 1982; Millar, 1982;
Siemann, 1982, 1984). However, the mechanisms of
chemosensitization, and in particular the role of
hypoxia, have not been completely elucidated.
Hypoxia during the MISO pretreatment stage has
been found to be essential for the in vitro
potentiation of all chemotherapy drugs studied to
date, including the enhanced cytotoxicity of the
bifunctional alkylating agent nitrogen mustard
(HN2) to V79 cells (Stratford et al., 1980) and
EMT6 tumour spheroids (Twentyman, 1982a,
1982b). A requirement of hypoxia for MISO
enhancement in vivo may explain why tumours
generally seem to be sensitized to a greater extent
than most normal tissues, although the exact
situation regarding the involvement of hypoxia in
vivo is unclear. However, Wheeler et al. (1984)
recently showed that, at least for the drug BCNU,
hypoxia induced by clamping of the leg was clearly
critical for sensitization by MISO of a
subcutaneous rat 9L tumour.
We recently reported (Murray & Meyn, 1984)
that pretreatment of mice with MISO enhanced the
in vivo DNA cross-linking activity of HN2 in a
murine fibrosarcoma, a tumour that contains a
substantial fraction of hypoxic cells (Stone & Milas,
1978; Grdina et al., 1976). The data suggested that
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sensitization in this case may be related to two
factors: glutathione (GSH) depletion giving rise to
an increased amount of DNA cross-linking, and a
subsequent inhibition of the repair of these cross-
links. Both the depletion of GSH (Varnes et al.,
1980; Bump et al., 1983) and the binding of MISO
to cellular macromolecules (Varghese & Whitmore,
1980; Miller et al., 1982; Bump et al., 1983), which
we supposed to be related to repair inhibition, have
been shown in vitro to be mediated by hypoxia;
thus, it seemed reasonable to assume that
nitroreduction of MISO to generate reactive
species, which is thought to require hypoxic
conditions (Biaglow, 1981), would also be a
prerequisite for chemosensitization in vivo.
In the present study, we have measured the effect
of pretreating mice with MISO on the initial level
of HN2-induced DNA cross-linking and on GSH
levels in a number of normal tissues and in two
fibrosarcomas. The importance of enhanced DNA
cross-linking in the sensitization of mammalian cells
to alkylating agents has been demonstrated in vitro
in the recent studies of Taylor et al. (1982, 1983),
who showed that the sensitization of Chinese
hamster ovary cells to melphalan by hypoxic
pretreatment with MISO can be quantitatively
accounted for by enhanced levels of DNA cross-
links. We show here that MISO pretreatment also
results in enhanced levels of HN2-induced DNA
cross-links in vivo, and further, that some normal
tissues are enhanced to a greater extent than the
tumours. These results suggest that some normal
© The Macmillan Press Ltd., 1984802 D. MURRAY & R.E. MEYN
tissues could be adversely sensitized should the
clinical use of combinations of antitumour drugs
with MISO or other chemosensitizing agents that
act by a similar mechanism be realized. These
observations are consistent with the hypothesis that
some normal tissues, though not hypoxic per se,
may be able to metabolize MISO to its active
nitroreduced derivative.
Materials and methods
Mice and tissue suspensions
Details of the specific pathogen-free C3H/Kam
mouse colony and of the NFSa tumour, which
arose spontaneously in these mice, have been
described elsewhere (Ando et al., 1979). The FSa
fibrosarcoma was originally induced by
methylcholanthrene (Suit & Suchato, 1967).
Tumours were grown by injecting 5 x 105 cells s.c.
into the hind legs of recipient mice, and were used
when they reached a mean diameter of 10-12mm.
Animals were sacrificed following the treatment
protocol, and the relevant tissues were quickly
removed and immersed in ice-cold Puck's solution
A (PSA) containing 5mM EDTA. Single-cell
suspensions were prepared from these tissues as
described elsewhere (Meyn & Jenkins, 1983). To
obtain NFSa cells, the viable tumour was excised,
finely minced with a razor blade, syringed with 8ml
of PSA through a 15-gauge needle, then filtered
through cotton gauze.
Alkaline elution
The alkaline elution technique originally devised by
Kohn (1979) for use with in vitro systems has been
adapted for use with in vivo systems using a
fluorometric DNA assay with the dye Hoechst
33258 (Cesarone et al., 1979; Murray & Meyn,
1983). To measure cross-linking using alkaline
elution, a constant number of single-strand breaks
were introduced into the DNA by irradiating the
cell suspensions in vitro on ice with 5Gy of X-rays
as discussed previously (Murray & Meyn, 1983).
These 5-Gy irradiated samples consequently eluted
much faster than their respective nonirradiated
controls. Treatment of mice with HN2 produced
cross-links in the DNA, which after irradiation with
5Gy in vitro, resulted in a slower rate of elution for
these samples than for the 5-Gy control with no
drug treatment. The DNA lesions produced after
treatment of cells with HN2 in vitro have been
shown to be of two types, namely proteinase K-
resistant and -sensitive cross-links; these are
presumably DNA-DNA interstrand and DNA-
protein cross-links respectively (Ewig & Kohn,
1977; Ross et al., 1978). We previously found
(Murray & Meyn, 1984) that the largest
contribution to the effect of HN2 on alkaline
elution profiles for the FSa tumour in vivo was due
to the DNA-protein cross-links. However, since
MISO pretreatment had little effect on the ratio of
DNA-DNA to DNA-protein cross-links and had
no selective effect on the repair of either type of
lesion, the present study was limited to an
examination of the total HN2-induced cross-links
(DNA-DNA and DNA-protein).
Suspensions were maintained on ice at all times
between excision of the tissue and onset of the
elution experiment to prevent repair of both the X-
ray-induced strand breaks and the HN2-induced
cross-links. Cross-linking factors (CLF) were
determined as described previously (Murray &
Meyn, 1983). A CLF of 1.0 represents no cross-
linking. All data presented are the average of at
least 4 separate experiments. Error bars refer to the
s.e. of the data.
GSH assay
Tissue levels of reduced GSH were estimated
fluorometrically using the GSH-specific dye
ophthalicdicarboxaldehyde (Hissin & Hilf, 1976).
Drug treatments
MISO (Hoffman La-Roche Inc., Nutley, N.J.) was
dissolved in 0.9% saline at 450 with periodic
agitation before use, and was injected i.p.
(1 mgg-1) 30min prior to the HN2 treatment. HN2
(Mustargen, Merck, Sharp and Dohme, West Point,
Pa.) was stored frozen at a concentration of
I00 gml 1 in a sodium chloride (I mgml1)
solution. For use, it was thawed and injected i.p.
Results
Typical alkaline elution profiles for DNA isolated
from tissues 1 h after mice were treated with HN2
alone (2mgkg-1) or were pretreated with MISO
(1mgg-1) 0.5h prior to injection with HN2
(2mgkg-1) are shown in Figure la for spleen and
lb for liver. That DNA from all tissues from mice
treated with HN2 eluted slower than that from
mice receiving no drug indicates HN2-induced
DNA cross-link formation. Thus, spleen showed a
relatively high level of HN2-induced cross-linking,
whereas liver showed a relatively low level. On the
other hand, pretreatment with MISO enhanced the
level of cross-linking substantially in the liver, but
had little effect on cross-linking in the spleen.
CLFs were calculated from alkaline elution
profiles such as those in Figure 1, and from similar
experiements with a variety of other tissues,
including the two tumours. The average values forCHEMOSENSITIZATION BY MISONIDAZOLE IN VIVO 803
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Figure 1 Typical alkaline elution profiles for (a) spleen and (b) liver, representing the following treatment protocols: * unirradiated control, no drug treatment; O 5-Gy-irradiated control, no drug treatment; 0 HN2 (2mgkg-1, i.p., h), then 5-Gy-irradiated; 0 MISO (1 mgg-', i.p., 0.5h) followed by HN2 (2mgkg- 1, i.p.
1 h), then 5-Gy-irradiated. Tissue suspensions were irradiated in vitro on ice immediately before alkaline elution analysis.
LI
Relative Cross-Ik Factor
Figure 2 DNA cross-linking factors measured in
mouse tumours and in representative normal tissues
I h after injection of mice with HN2 (2mgkg-1, i.p.).
Shaded areas refer to animals treated with HN2 alone.
Unshaded areas represent the additional cross-linking
produced in these tissues in mice pretreated with
MISO (1 mgg-1) for 0.5h prior to injection with
HN2.
the CLFs for different tissues after a single dose of
HN2 (2 mgkg-1), with or without MISO
pretreatment, are shown in Figure 2. It is
interesting to note that the degree of cross-linking
1 h after treatment with HN2 alone varied
substantially among the different tissues. Of the
tissues studied, liver showed a markedly lower level
of cross-linking after HN2 alone than did the
others, while spleen and jejunum showed the
highest levels. It is apparent that MISO had little
effect on cross-linking in spleen or jejunum; however, in all other tissues examined, cross-linking
was enhanced by MISO to a varying extent. Cross-
linking enhancement factors for each tissue,
calculated from the data in Figure 2, are presented in Table I. The greatest enhancement was observed
in liver (x 6). Of the other normal tissues, only kidney (x 3.1) had an enhancement factor greater than the two tumours. Cross-linking in both brain
(x 1.44) and bone marrow (x 1.95) wqs enhanced, but to a lesser degree than for either tumour.
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Table I Cross-linking enhancement factors determined
from the ratio of DNA cross-links measured 1 h after
injection of mice with HN2 (2mgkg-1), with or without a












cross-linking in a dose-modifying manner, CLF
dose-response relationships were determined at 1 h
postinjection over a range of HN2 dosages, both
with and without MISO pretreatment, for selected
tissues. The dose-responses for FSa have been
published previously (Murray & Meyn, 1984); those
for NFSa and spleen were also linear (data not
shown) within the concentration range studied
(0-4mgkg-1). Based on the observed linearity of
these dose-responses, the enhancement of DNA
cross-linking by pretreatment with MISO (Table I
and Figure 2) appears to represent true dose-
modification, and the calculated "enhancement
factor" is therefore independent of the HN2 dosage
over this dose range.
Control experiments using alkaline elution
analysis (data not shown) showed that treatment
with MISO alone for up to 1.5 h produced no
detectable strand-breakage in DNA isolated from
any of the tissues studied except in the case of
NFSAa, where a small number of breaks were ob-
served. Likewise, neither HN2 alone, nor MISO
plus HN2, caused any DNA strand-breakage 1 h
after injection with HN2. As we reported previ-
ously, (Murray & Meyn, 1984), treatment with
MISO alone for periods between 0.5-1.5h did
produce a slight retarding effect on the 5-Gy-
irradiated control elution profiles for DNA isolated
from FSa tumours; however, no evidence for such
an interaction between MISO and DNA was ob-
served in any of the other tissues examined in this
study, including NFSa.
Since the cytotoxic effects of HN2 may be subject
to modification by intracellular thiols, we
investigated the effect of MISO (1 mgg-1) on GSH
levels in selected tissues as a function of time after
injection. These results are shown in Table II. Data
for GSH levels in FSa, liver, and spleen, are similar
to those reported previously (Murray & Meyn,
1983). There was a moderate degree of GSH
depletion in each tissue, with the exception of
spleen. The largest depletion of any tissue was in
liver (62% of control at 1 h), with the other tissues
typically being depleted to 80-90% of control after
I h.
Discussion
The ability of MISO to potentiate the action of
HN2 at the DNA-lesion level is evidently not a
phenomenon restricted to neoplastic tissues, since
some normal tissues, particularly liver and kidney,
are also sensitized in terms of cross-link formation
to varying degrees (Table 1). Assuming that HN2-
induced DNA cross-links represent the lesions
responsible for the cytotoxicity of this drug, these
results may have important implications in
chemosensitization. The basic mechanisms
underlying this effect are still uncertain, and in an
attempt to clarify this situation, the various
metabolic factors that could influence the
interaction between MISO, HN2 and DNA in vivo
must be considered.
An important parameter determining the
sensitivity of mammalian cells in general to the
cytotoxic effects of alkylating agents is their GSH
concentration, since GSH can protect cells by
detoxifying electrophilic drugs such as HN2 (e.g.,
see Millar, 1982). Thus, not only would cellular
GSH levels be expected to affect the intrinsic
sensitivity of a particular tissue, but modification of
GSH levels should also result in altered intracellular
inactivation of HN2, effectively changing the drug
concentration at the target molecule(s). Prolonged
Table II Glutathione levels in tumour and selected normal mouse
tissues before and after injection with MISO (1 mgg-1, i.p.).
GSH concentration % ofcontrol value after MISO
Tissue ,molg-1 JIh 2h 4h
FSa 0.54+0.20 88+7 75+5 87+9
NFSa 1.55+0.32 90+3 87+3 82+5
Liver 3.65+1.12 62+1 68+9 66+8
Spleen 1.64+0.15 100+2 99+5 108+2
Kidney 1.90+0.14 82+1 94+5 90+4CHEMOSENSITIZATION BY MISONIDAZOLE IN VIVO 805
exposure of mammalian cells to MISO results in
depletion of thiols in vitro, but only under hypoxic
conditions (Varnes et al., 1980; Bump et al., 1983),
suggesting that the interaction requires prior
nitroreduction of MISO. The biochemical
mechanisms of cellular reduction of
nitroheterocyclic compounds such as MISO by
nitroreductases to generate oxygen-reactive
intermediates, and the role of thiols in the
detoxification of these species, have been
extensively discussed by Biaglow (1981). It should
be noted that the capacity of a cell to reduce nitro
compounds to the one electron reduction product,
the nitro radical anion, does not depend on the
state of oxygenation; rather, under aerobic
conditions, further reduction of this species is
inhibited by reaction with oxygen. For the
remainder of this discussion, the term
"nitroreduction" will be taken to imply that other
processes, such as the addition of further electrons
to the MISO radical anion, can efficiently compete
with molecular oxygen. In the extreme case, a
further five electrons may be added to generate the
2-aminoimidazole derivative (Biaglow, 1981).
The possible relationship between the removal of
nonprotein thiols and the enhancement of the initial
level of HN2-induced DNA lesions in vivo can be
examined by comparing the degree of GSH
depletion in a particular tissue 1 h after injection
with MISO (Table II) with the cross-linking









HN2 injection, i.e. before the lesions appear to be
significantly affected by cellular repair processes. A
period of 1 h was selected on the basis of results
from a previous study with the FSa tumour
(Murray & Meyn, 1984). The data for five tissues,
liver, FSa, NFSa, kidney and spleen, are shown in
the form of a correlation plot in Figure 3a. Linear
regression analysis of these data shows a strong
correlation between lowering of GSH levels by
MISO and enhancement of the initial yield of DNA
cross-linking induced by HN2 (correlation
coefficient 0.99). These results support our previous
conclusion, based on the effect of the GSH-
depleting reagent diethyl maleate on HN2 cross-
linking in the FSa tumour, that the initial phase of
cross-linking enhancement (0-1 h) is primarily due
to MISO-induced depletion of GSH (Murray &
Meyn, 1984).
Since both chemosensitization and GSH
depletion in vitro would appear to require
anaerobic nitroreduction of MISO, a similar
requirement for hypoxia would be anticipated in
vivo. In a recent study of X-ray-induced DNA
strand-breaks in mice, the observed response was
explained by assuming that normal tissues are
radiobiologically hypoxic to varying degrees (Meyn
& Jenkins, 1983). Tissues such as spleen and bone
marrow, which were more responsive to X-rays,
were considered to be relatively well oxygenated,
whereas resistant tissues such as liver, jejunum, and
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Figure 3 (a) Relationship between initial DNA cross-linking enhancement factors and the degree of MISO-
induced glutathione depletion in five selected mouse tissues; liver (-), kidney (0), FSa (O), NFSa (O) and
spleen (O). (b) Relationship between initial DNA cross-linking enhancement factors and the degree of
residual 14C-activity in normal mouse tissues measured 72h after i.p. injection of mice with 14C-MISO (data
from Garrecht and Chapman, 1983). Tissues included are liver (0), kidney (0), brain (s), jejunum (*) and
spleen (<>).
D
1(806 D. MURRAY & R.E. MEYN
more hypoxic. Comparison of the degree of cross-
linking enhancement observed here (Table I) with
an estimate of relative hypoxia, based on the X-ray
response from Meyn & Jenkins (1983) for a
particular tissue, suggests little correlation between
these events. For example, although bone marrow
appeared from its reponse to X-rays to be relatively
well oxygenated, it was enhanced by a factor of
almost 2 (Table I), whereas jejunum, a relatively
more hypoxic tissue, showed no enhancement.
Thus, although normal tissue hypoxia may be
important in the response to X-rays, additional
factors may play a more important role in
chemosensitization. This apparent difficulty in
resolving the involvement of hypoxia per se in the
chemosensitization of normal tissues in vivo may be
due to the metabolism of MISO at non-hypoxic
loci, as discussed below.
In addition to the interaction between MISO and
GSH, the binding of MISO-metabolites to cellular
macromolecules also requires nitroreduction, as
demonstrated in anaerobic mammalian cells in
vitro. Miller and co-workers (1982) have recently
reported that the binding of 14C-MISO is 55 times
more rapid in EMT-6 tumour cells made hypoxic in
vitro than in well-oxygenated cells. This same
requirement would also be expected in vivo,
suggesting that binding and accumulation of MISO
metabolites in tissues is a measure of the degree of
nitroreduction occurring in those tissues. Chin &
Rauth (1981) have demonstrated extensive
metabolism and retention of 14C-labelled MISO in
mouse liver, and to a lesser extent in kidney,
whereas little evidence of metabolism was seen in
brain or spleen. Analysis of the metabolic products
showed the presence of a considerable proportion
of the amino derivative in both liver and kidney,
suggesting that appreciable nitroreduction occurred
in these tissues. Garrecht & Chapman (1983) have
also studied the clearance of 14C-labelled MISO
from mouse tissues, and again marked retention of
14C was observed in the liver, as well as in regions
of tumours considered to be hypoxic. Retention by
liver was suggested to be related to unique
biochemical activities involved in drug
detoxification rather than to the existence of a low
oxygen tension in liver relative to other normal
tissues. All of the other normal tissues retained
small but measurable levels of radioactivity even up
to 72h after MISO injection.
In Figure 3b, 1 h cross-linking enhancement
factors (data from Table I) for 5 normal tissues are
plotted against the values for the relative amount of
'4C retained in these tissues 72h after injection with
14C-labelled MISO taken from the data of Garrecht
& Chapman (1983). The reasonably good linear fit
to these points (correlation coefficient of 0.92)
suggests that the enhancement of HN2 cross-linking
in normal tissues such as liver and kidney, and by
inference in tumours, may be intimately related to
the generation and/or accumulation of nitro-
reduced MISO metabolites in a given tissue. The
occurrence of cellular events in vivo such as MISO-
induced thiol depletion and binding of labelled
MISO to cellular macromolecules, both of which
have been shown to be nitroreduction-dependent in
vitro, appear to be good indicators for the ability of
a particular tissue to undergo chemosensitization.
While GSH depletion can apparently account for
the enhancement of initial DNA damage (0-1 h) in
each tissue as discussed above, it appears that this
increased burden of lesions may represent only one
component of the overall mechanism of the
sensitization process, at least in the case of the FSa
tumour; the binding of MISO to cellular
macromolecules (DNA or repair enzymes?) may be
responsible for the subsequent inhibition of cross-
link repair that was observed with FSa in the period
1-6h after injection with HN2 (Murray & Meyn,
1984). Such repair inhibition may actually represent
a major component of chemosensitization, and this
possibility is presently being investigated. Since
both GSH depletion and cellular binding of MISO
are nitroreduction-dependent, it would not be
surprising if the two proposed resulting effects, i.e.
enhanced initial damage and decreased rate of
repair of this damage, were necessarily
concomitant; however, preliminary unpublished
data from our laboratory suggest that this may not
be the case, since some tissues do not appear to
exhibit such repair inhibition.
It has been suggested that MISO-induced
pharmacokinetic alterations may also contribute to
chemosensitization, particularly after single high
doses of MISO (0.8-1.Omgg-1) (Millar, 1982;
Siemann, 1982), and may be an especially
important mechanism in the case of the drugs
CCNU (Lee & Workman, 1983) and melphalan
(Clutterbuck et al., 1982; Hinchliffe et al., 1983).
Brown & Hirst (1982) showed that a protocol
involving multiple low doses of MISO, designed to
mimic human serum levels of the drug, still
sensitized the RIFI sarcoma to both melphalan and
cyclophosphamide, with no associated increase in
normal tissue toxicity as measured by white blood
cell counts, bone marrow colony-forming units, or
testicular damage. Chronic low-dose MISO
protocols were subsequently shown to have no
effect on melphalan serum levels (Hinchliffe et al.,
1983), suggesting that pharmacokinetic alterations
in mice may be unique to the use of acute high-
dosage MISO, and thus are unlikely to be
important in the clinical situation. In the case of
HN2, MISO-induced pharmacokinetic changes probably do not contribute significantly to the ob-
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conclusion is further supported by the present data,
since the absence of sensitization to HN2 in tissues
such as spleen and jejunum is inconsistent with a
generalized alteration of serum pharmacokinetics
being a major mechanism. This is not to suggest
that pharmacokinetic effects may not be important
in the enhancement of other cross-linking agents
after acute high doses of MISO. Workman et al.
(1983) have shown that one action of MISO is to
inhibit the metabolism of other cytotoxic drugs in
the liver, particularly those pathways involving
cytochrome P450. We previously examined the
effect of MISO on melphalan-induced DNA cross-
linking in mouse tissues (Murray & Meyn, 1983),
and reported enhancement factors of 1.5 for the
two normal tissues (spleen and jejunum) that
showed no enhancement with HN2. For spleen,
which appears to be relatively well oxygenated and
showed no MISO-induced GSH depletion, this
result was initially surprising. However, it now
appears that the sensitization of spleen and jejunum
to melphalan is due largely to pharmacokinetic
effects associated with this drug as discussed above.
The observation of extensive damage to DNA in
normal tissues after treatment with the alkylating
agent alone is not surprising in view of the known
toxicity pattern characteristic of HN2. The normal
tissue toxicities of HN2 largely parallel those of
other agents that are specific for proliferating cells,
e.g. damage to the haematopoietic and immuno-
logical systems and to the gastrointestinal mucosa
(Ochoa, 1969; Calabresi & Parks, 1980). Previous
studies have failed to show a selective uptake of
alkylating agents in those tissues showing severe
injury (bone marrow, lymph nodes, intestinal
epithelium or tumour tissues) (Ochoa, 1969). This
lack of selective drug localization in tumours led
Ochoa (1969) to conclude that any therapeutic
advantage with HN2 must reside in factors other
than distribution. The present data confirm that
this lack of selective tumour effect is also evident at
the molecular lesion level; the tissues showing the
greatest level of DNA damage were the jejunal
mucosa and spleen, while bone marrow showed a
much lower level of cross-linking comparable to
that measured in the two tumours. This apparent
lack of correlation between toxicity and the level of
DNA damage may reflect the fact that in the
present study we have measured an effect that
represents an average of all of the cells in a
particular tissue, regardless of heterogeneity; the
toxic effects of the drug, however, are probably
determined primarily by the response of the
clonogenic cells which may only represent a small
fraction of the total population.
In summary, we have shown that while
pretreatment of mice with MISO potentiates HN2-
induced DNA cross-linking in two fibrosarcomas in
vivo, the potential clinical application of
chemosensitization is unclear, since four of the six
normal tissues examined were also enhanced to
varying degrees. In fact, DNA damage in liver was
potentiated to a greater extent than in either
tumour, although there was only a very low level of
cross-linking in this tissue after treatment with HN2
alone. Assuming that the mechanism and pattern of
sensitization is similar for other antitumour agents,
enhancement of hepatotoxicity and nephrotoxicity
might be expected to be potentially limiting factors
in the application of MISO in combination with
certain drugs, and should be further investigated
with biological end-points for impaired organ
function. It should be noted that the present study
employed a particular scheduling and dosage of the
two drugs based on a previous study (Murray &
Meyn, 1984). Both thiol depletion (Varnes et al.,
1980) and binding of MISO to cellular
macromolecules (Varghese & Whitmore, 1980;
Miller et al., 1982) are time-dependent processes,
and therefore drug scheduling is likely to be an
important aspect of chemosensitization. In
particular, varying the time between injection of
MISO and HN2 could result in sensitization of
tissues not affected in the present study and/or
abrogate the degree of sensitization that was
observed.
This investigation was supported by USPHS grant CA
23270 awarded by the National Cancer Institute,
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